The Smartest Biotech Investment of the Decade
How did Warren Buffett become a billionaire? He didn't chase trends—he understood the businesses he invested in. By the time a hot tip reaches Main Street, it’s already too late.
Think about an opportunity you missed. What made you pass on it? Smart
investors dig deep—from stock prices to financial statements to the CEO’s
track record. But in biotech, the game changes. The stakes are higher, the
requirements more complex.
While some have billions on smart biotech stocks, most have lost. A
staggering 90% of biotech startups fail[i],
and the very reason they fail holds the key to success for one small
company.
Beat the Billionaires: An Overlooked Stock with Game-Changing Potential
Biotech companies are a unique breed, running on billions in capital with
only hypothetical products. Sounds insane, right? But imagine the potential. The fortunes of Jeff Bezos and Bill Gates would look modest compared to the windfall if a biotech company cures cancer, Alzheimer’s, Parkinson’s, or another devastating disease.
It’s no wonder investors flock to sexy stocks that offer to one day cure or detect these diseases, but that often comes at a cost, and that cost is usually paid by the investors.
Consider this: Ultra-wealthy investors like Bezos and Gates poured billions into a company called Grail,[ii][iii] which aimed to detect cancer early. In just a few years, it was snapped up by Illumina for $8 billion,[iv][v] briefly looking like the Holy Grail of biotech. But then, antitrust suits from the EU and USA sent Illumina spiraling, costing investors billions and leaving Grail without a home, desperately needing capital. Without $500 million a year in additional[vi] capital, Grail has little chance of success. And it’s not alone—90% of pharmaceuticals never make it to FDA trials.[vii]
They fail because they focus on potential impact, not the business of biotech. They rely on investors to carry them until a breakthrough, then move on to the next one if it fails.
A Business-Focused Approach to Biotech Success
There’s a formula for biotech success, and it usually won’t make front-page headlines—until it succeeds. And that’s how investors like Buffett made their fortunes: by investing in businesses that have a plan, instead of the trend-chasers.
Enter two clinically trained pharmacists turned business executives. They
believe they’ve cracked the code to join the elite 10% of biotech companies that succeed. Their company, Tharimmune (THAR), could be the biggest biotech opportunity of the decade. Miss out, and it might be your biggest investing regret ever.
This company was formed to find better options for treatment-resistant cancers because the successful founder lost his brother to one of these forms of cancer.
What may seem crazy to investors is that Tharimmune’s (THAR) first drug has nothing to do with these types of cancer, in fact, it focuses first on helping patients with a form of incessant itching. Not itching to get on board yet? You should be…
What makes this the smartest biotech play of the decade isn’t in the first drug, or even the second, what is brilliant about what these two executives are doing is rooted in their business strategy of simple viability.
That is, getting a product to market quickly, creating a profit, and continuing to grow and expand!
It’s an understanding like this that helped founder Randy Milby grow his last biotech venture from a $3M start up to a $350M moonshot.*
So while every other biotech is pulling on heartstrings and pedaling for investor money with pie in the sky solutions, Milby and his COO Sireesh Appajosyula are working tirelessly to build a practical and sustainable business.
Already FDA Approved: The Secret Weapon Against Bankruptcy
Did you know Colgate spent $38 million and 10 years developing a toothpaste ? They introduced a new additive, and it took over a decade to get it approved, illustrating just how difficult bringing a new drug to market is. That’s why most biotechs run out of cash and fail. They put all their eggs in one capital-intensive basket, often ending in bankruptcy, crushed under the weight of the FDA approval process.
It’s a pitfall that COO Sireesh Appajosyula has years of experience avoiding. After spending 8 years at Salix Pharmaceuticals, a company he helped to grow from being worth millions to billions, the new COO of Tharimmune has seen his share of both loss and success stories.
But thanks to Milby and Appajosyula, Tharimmune (THAR) is on the brink of delivering a solution to the capital dilemma with the FDA approved active ingredient, Nalmefene. Initially used to treat overdoses, its unique chemical makeup also makes it a perfect candidate for treating Chronic Pruritus (extreme itchiness).
And the best part?: the patent for this already approved drug covers only the nasal spray. Allowing Tharimmune’s team to devise a new, clever delivery mechanism—a dime-sized oral patch. This patch sticks to the inside of the cheek, delivering the drug straight into the bloodstream, bypassing the overworked liver. It could end Chronic Pruritus for good. And since it is only the oral patch delivery version of nalmefene, which is an approved molecule, that the FDA has to consider, it could dramatically expedite the process.
Fast-Track to Success: Tharimmune’s Groundbreaking Timeline
Tharimmune (THAR) oral patch potentially solves a problem plaguing 1.7 million people in the US alone, delivering relief directly into the bloodstream. This means that unlike other biotechs that take decades to bring a product to market, Tharimmune is on a fast track. And with Phase II testing slated to begin in 2024, this product could hit the shelves as early 2026. That’s less than two years away!
Think about it…Once the delivery mechanism is approved, how many other drugs can be delivered using this patch? How many other symptoms can be treated and products sold thanks to the foresight of this business approach?
For biotech investors, this is music to their ears. They’ve seen too many companies, like Sorrento Therapeutics and Humanigen, go bankrupt. But Tharimmune’s drug is already FDA-approved; they just need the patch to pass. And with their experienced leadership, a rapid timeline, and $10 million earmarked for Phase II testing, this could be the golden opportunity you’ve been waiting for.
When it comes to beating the billionaires to the finish line and out-pacing their competition, Tharimmune (THAR) knows what it takes to succeed, and even better, how to do it again…and again…and again!
But don’t just take my word for it. I’ve included endnotes to get you started on your own research. And you should know that even companies under impressive leadership like Tharimmune carry a certain amount of risk. So you should never invest more than you are willing to lose. However…
As you and your financial advisor should come to agree, you won’t want to let this ground-breaking opportunity slip away. Click the link below to learn how Tharimmune could transform your investment portfolio in less than two years. Act now—before you’re reading about this biotech behemoth in the paper!! Click the link below now!
P.S. Still want more information on Tharimmune, Inc. (THAR)?
Sign up below for Tharimmune’s Investor Presentation, and breaking news about this and other interesting companies, completely free. Sign up below to learn about this investment opportunity.
By signing up above, Wall Street Fundamentals will send the latest investor report to the email provided. You'll also receive special reports completely free. You can unsubscribe at any time. View our Privacy Policy here.
IMPORTANT NOTICE AND DISCLAIMER
THIS PUBLICATION IS AN ISSUER-PAID ADVERTISEMENT.
This paid advertisement includes a stock profile of Tharimmune (THAR). To enhance public awareness of THAR and its securities, the issuer has provided Promethean Marketing, Inc. (“Promethean”) with a total budget of approximately one hundred seventy thousand dollars ($170,000.00) USD to cover the costs associated with this advertisement for a period beginning 7 July 2024 and currently set to end 8 August 2024. This compensation should be viewed as a major conflict with our ability to be unbiased. The website hosting this advertisement, Wall Street Fundamentals, is owned by Promethean. As a result of this advertisement, Wall Street Fundamentals may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. Promethean will retain any excess sums after all expenses are paid. As of the date this advertisement is posted to the Wall Street Fundamentals website, some or all of Promethean or Wall Street Fundamentals and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) may hold the securities of THAR and may sell those shares during the course of this advertising campaign. This advertisement may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of THAR, increased trading volume, and possibly an increased share price of THAR’s securities, which may or may not be temporary and decrease once the advertising campaign has ended. This communication is based on information generally available to the public and on interviews with THAR Management, and does not (to the Publisher’s knowledge, as confirmed by THAR) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, neither Promethean or Wall Street Fundamentals cannot guarantee the accuracy or completeness of the information. To more fully understand the Wall Street Fundamentals website or service, please review its full Disclaimer and Disclosure Policy located here.
[i] https://www.axios.com/2023/03/13/silicon-valley-bank-failure-spooks-health
[ii] https://www.geekwire.com/2020/bill-gates-jeff-bezos-backed-cancer-detection-company-grail-led-ex-juno-ceo-files-ipo/
[iii] https://investor.illumina.com/news/press-release-details/2020/Illumina-to-Acquire-GRAIL-to-Launch-New-Era-of-Cancer-Detection/default.aspx
[iv] https://investor.illumina.com/news/press-release-details/2020/Illumina-to-Acquire-GRAIL-to-Launch-New-Era-of-Cancer-Detection/default.aspx
[v] https://www.reuters.com/markets/deals/rocky-history-illuminas-grail-deal-2023-06-06/
[vi] https://www.linkedin.com/pulse/grail-divestment-perspectives-valuation-its-potential-pierre-ars%C3%A8ne-txtqe/
[vii] https://www.linkedin.com/pulse/fail-fast-often-forward-lessons-biotech-innovation-resilience-bose-6cpce/
* past performance is not a promise of future results.
end note: past performance is not a promise of future results.